Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Camzyos“
Suchtreffer
Begriffe & Kennungen
Camzyos
Eintrag öffnenCamzyos · 4.1 Therapeutic indications · 1
Eintrag öffnenCamzyos · 4.3 Contraindications · 1
Eintrag öffnenCamzyos · 4.3 · ▪ Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. ▪ During pregnan
Eintrag öffnenCamzyos · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenCamzyos · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenCamzyos · 4.5 · 10 Table 2: Dose modification/monitoring of mavacamten with concomitant medicinal products
Eintrag öffnenCamzyos · 4.5 · 11 Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and u
Eintrag öffnenCamzyos · 4.5 · 12 Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and u
Eintrag öffnenCamzyos · 4.5 · 9 Pharmacokinetic interactions
Eintrag öffnenCamzyos · 4.5 · CYP2C19 and CYP3A4 inducers No clinical interaction studies were conducted to investigate the effect of concom
Eintrag öffnenCamzyos · 4.5 · CYP2C19 inhibitors The effect of a moderate and strong CYP2C19 inhibitor on the PK of mavacamten was not inves
Eintrag öffnenCamzyos · 4.5 · CYP3A4 inhibitors The effect of strong CYP3A4 inhibitors on the PK of mavacamten was not investigated in a cli
Eintrag öffnenCamzyos · 4.5 · Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and ultr
Eintrag öffnenCamzyos · 4.5 · Discontinuing a moderate or weak inducer while on mavacamten treatment: Decrease mavacamten by one dose level
Eintrag öffnenCamzyos · 4.5 · Discontinuing or decreasing the dose of moderate or weak inducer while on mavacamten treatment: Decrease mavac
Eintrag öffnenCamzyos · 4.5 · Effect of mavacamten on other medicinal products Mavacamten in vitro data suggest a potential induction of CYP
Eintrag öffnenCamzyos · 4.5 · Effect of other medicinal products on mavacamten In CYP2C19 intermediate, normal, rapid and ultra-rapid metabo
Eintrag öffnenCamzyos · 4.5 · If treatment with a new negative inotrope is initiated or if the dose of a negative inotrope is increased in a
Eintrag öffnenCamzyos · 4.5 · Pharmacodynamic interactions
Eintrag öffnen